An inability to distinguish between CIDP and POEMS syndrome can negatively affect treatment strategies and outcomes. A 2-step protocol using conduction block and maximum/minimum cross-sectional area ...
The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). "This medication has a novel ...
Investigational therapies may soon change the treatment landscape for chronic inflammatory demyelinating polyneuropathy (CIDP). "Despite the fact that we have some good standard-of-care therapies -- ...
CIDP significantly affects daily life, with many patients needing mobility aids and caregiver support, impacting employment and quality of life. A real-world survey showed 22% of CIDP patients were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results